Literature DB >> 1969342

Peptides derived by processing of rat prosomatostatin near the amino-terminus: characterization, tissue distribution, and release.

S N Rabbani1, Y C Patel.   

Abstract

Mammalian prosomatostatin (pro-S) undergoes extensive processing at the C-terminal segment where the somatostatin-like biological activities (S-14 and S-28) reside. The recent discovery of pro-S-(1-10) (antrin) as a prominent mature product in the stomach suggests that pro-S may also be processed at the N-terminus. In the present study we have developed an antibody directed against the N-terminal segment of pro-S-(1-10) capable of detecting peptides extended at the C-terminus of pro-S-(1-10) to characterize N-terminal processing of rat pro-S. Specifically, we have 1) examined the relative abundance of pro-S-(1-10)-like immunoactivity [pro-S-(1-10)] in different somatostatin tissues as an index of tissue-specific N-terminal processing, 2) compared the concentrations of pro-S N- and C-terminal immunoreactive peptides, 3) used HPLC and region-specific RIAs directed against both the N- and C-terminal segments of pro-S to identify and characterize novel N-terminal peptides, 4) studied the tissue distribution and release of the N-terminal peptides; and 5) characterized and quantified a 7-kDa molecule equivalent to pro-S without the C-terminal S-28 sequence. Acetic acid (1 M)-pepstatin extracts of hypothalamus, cerebral cortex, antrum, jejunal mucosa, and pancreas were fractionated by reverse phase and gel permeation HPLCs. Whole tissue extracts as well as the column effluent were monitored by region-specific RIAs using antibodies against pro-S-(1-10), S-28-(1-12), and S-14. Other than the pancreas, all S-producing tissues were rich in pro-S-(1-10) LI. Its concentration was 1- to 4-fold lower than those of S-14 LI and S-28-(1-12) LI. Tissue pro-S-(1-10) LI was heterogeneous, consisting of at least eight molecular forms with respective mol wt of 1,000 (1 kDa), 1,500 (1.5 kDa), 2,500 (2.5 kDa), 3,500 (3.5 kDa), 4,500 (4.5 kDa), 7,000 (7 kDa), 8,000 (8 kDa), and 10,000 (10 kDa). Based on the simultaneous presence or absence of C-terminal immunoreactivity, the 10-kDa form corresponded to pro-S, 8 kDa to pro-S-(1-76), and 7 kDa to pro-S without the S-28 sequence. The predominant N-terminal forms corresponded to 1 kDa [pro-S-(1-10)] and 7 kDa. The 1-, 1.5-, 2.5-, and 7-kDa forms were identified as secretion products in portal blood or in medium from cultured 1027 B2 islet somatostatin cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1969342     DOI: 10.1210/endo-126-4-2054

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  8 in total

Review 1.  Molecular biology of the regulation of hypothalamic hormones.

Authors:  J M Rondeel; I M Jackson
Journal:  J Endocrinol Invest       Date:  1993-03       Impact factor: 4.256

2.  Heterologous processing of rat prosomatostatin to somatostatin-14 by PC2: requirement for secretory cell but not the secretion granule.

Authors:  A S Galanopoulou; N G Seidah; Y C Patel
Journal:  Biochem J       Date:  1995-10-01       Impact factor: 3.857

3.  Human seminal plasma contains somatostatin-64.

Authors:  L Odum; A H Johnsen
Journal:  Biochem J       Date:  1994-10-01       Impact factor: 3.857

4.  Direct role of furin in mammalian prosomatostatin processing.

Authors:  A S Galanopoulou; N G Seidah; Y C Patel
Journal:  Biochem J       Date:  1995-07-01       Impact factor: 3.857

5.  Somatostatin in inflammatory bowel disease.

Authors:  J D van Bergeijk; J H Wilson
Journal:  Mediators Inflamm       Date:  1997       Impact factor: 4.711

6.  The relationship between N-terminal prosomatostatin, all-cause and cardiovascular mortality in patients with type 2 diabetes mellitus (ZODIAC-35).

Authors:  Peter R van Dijk; Gijs W D Landman; Larissa van Essen; Joachim Struck; Klaas H Groenier; Henk J G Bilo; Stephan J L Bakker; Nanne Kleefstra
Journal:  BMC Endocr Disord       Date:  2015-04-14       Impact factor: 2.763

Review 7.  Biological redundancy of endogenous GPCR ligands in the gut and the potential for endogenous functional selectivity.

Authors:  Georgina L Thompson; Meritxell Canals; Daniel P Poole
Journal:  Front Pharmacol       Date:  2014-11-28       Impact factor: 5.810

8.  N-Terminal Prosomatostatin as a Risk Marker for Cardiovascular Disease and Diabetes in a General Population.

Authors:  Tore Hedbäck; Peter Almgren; Peter M Nilsson; Olle Melander
Journal:  J Clin Endocrinol Metab       Date:  2016-07-11       Impact factor: 5.958

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.